Acrostar SMO is a site management organization wholly-owned by the Novotech Health Holdings Group and set up branches and offices in Shanghai, Beijing, Nanjing, Guangzhou, Shenzhen, Hangzhou, etc.
Our business covers 28 provinces, autonomous regions and municipalities. Since its establishment in 2017, the business volume of Acrostar has been growing per year, making it one of the fastest growing SMO in China in recent years.
- Passed on-site inspection by NMPA for the first time.
- Transformation of operations from Phase I to Phase II/III;
- Undertaking the first multinational drug company oncology trial;
- Undertaking the first cell therapy (CAR-T) project.
- The company was renamed Acrostar site management Co.,Ltd. Registered in Nanjing;
- More than 60 cooperative companies, including 30 foreign-funded enterprises;
- Became a preferred supplier of 12 GCP hospital.
- Expanded business scope to 27 provinces, autonomous regions and municipalities. And covering more than 60 cities, all with full-time CRCs;
- The company developed a talent training plan to strengthen the staff sense of belonging.
- Cooperation with over 400 GCP centres, and adding to the list of preferred supplier of dozens of hospitals;
- The number of collaborating clients exceeded 150.
- Overcoming the difficulties of a three-year epidemic. Multiple project teams prepare for NMPA verification;
- Improve the team structure, bring in excellent managers and strengthen the management team;
- Became a preferred supplier of several GCP centres.
- Supporting product approvals and market launches for multiple projects in development;
- Introduced and built project management system;
- Completed verification of several MNC companies and became their preferred supplier, with a 20% growth in business from the previous year.